TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03493373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
Study: NCT02178592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV 600 mg
Description: EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
Study: NCT01778049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Study: NCT00511433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP-EE
Description: Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
Study: NCT00496197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eraxis (anidulafungin)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diflucan (fluconazole)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
Study: NCT03580642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eHealth Technologies
Description: The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
Study: NCT03773133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide tetraxetan
Description: Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan
Description: Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
Study: NCT03794206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vesair Balloon
Description: Treatment with Vesair Balloon for one year
Study: NCT01552785

Intervention type: DEVICE
Intervention: Peripheral near infrared spectroscopy
Description: Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
Study: NCT02854124

Intervention type: PROCEDURE
Intervention: Melanoma and peritumoral skin excision
Description: Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
Study: NCT01900301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal placebo
Description: Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
Study: NCT02497378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54767414 (Daratumumab)
Description: JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
Study: NCT03792867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
Study: NCT02497378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
Study: NCT00773786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol (Brovana)
Description: twice daily via nebulizer added to maintenance daily tiotropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 1 week (added to maintenance tiotropium)
Study: NCT02112682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion axillary treatment
Description: Completion axillary treatment according to the Dutch breast cancer guideline
Study: NCT00613925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pipelle de Cornier
Description: A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Explora curette
Description: The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
Study: NCT04376736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Description: Home visit by medical provider
Study: NCT06307210

Intervention type: OTHER
Intervention: inpatient rehabilitation
Description: physiotherapy (strength and endurance training), occupational therapy and neuropsychological training

Intervention type: OTHER
Intervention: inpatient rehabilitation
Description: physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
Study: NCT02380703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggression Prevention Training (APT)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Primary Care (EU-PC)
Study: NCT01502189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Representational approach
Description: The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
Study: NCT04926350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 8 total resistance exercises that target all major muscle groups
Study: NCT00035620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: pegfilgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: filgrastim
Study: NCT01214954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training
Description: Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
Study: NCT02484729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977, oral suspension
Description: Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, oral suspension
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977, oral solution
Description: AZD9977, single dose of oral solution in Part B as reference
Study: NCT03061331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 400 mg/IVA 250 mg every 12 hours (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 400 mg/IVA 250 mg every 12 hours (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No Active Drug
Study: NCT01888133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Walk
Description: weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Walk
Description: weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Walk
Description: engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Walk
Description: engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
Study: NCT03798730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solid Model
Description: Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages.
Study: NCT03282110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ta-VNS
Description: The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
Study: NCT00659100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 50 mg oral capsule 30 minutes before bedtime
Study: NCT02891681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound
Study: NCT03061331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No Active Drug
Study: NCT01064999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
Study: NCT01571973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacotherapeutic follow-up
Description: health education adjustment of dose improve compliance replacement of medication
Study: NCT03395704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LJPC-401
Description: LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
Study: NCT01980875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
Study: NCT01980875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: 2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: 1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
Study: NCT03183375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
Study: NCT01064999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: High intensity group:55Gy Low intensity group:50Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: High intensity group:55Gy Low intensity group:50Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Lower anterior resection or abdominoperineal resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Lower anterior resection or abdominoperineal resection
Study: NCT01160588

Intervention type: DRUG
Intervention: Sertraline
Description: Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
Study: NCT00336505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethromycin
Description: Cethromycin 300 mg once per day (QD) for 7 days, administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Study: NCT04627896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Katty focal therapy
Description: Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
Study: NCT03067857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
Study: NCT03183349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deprotienized bovine bone (tutogen)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin
Study: NCT00770874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 + Cisplatin (arm A)
Description: S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (arm B)
Description: Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
Study: NCT03944694

Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium assessment.
Description: Full blood count analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium assessment.
Description: Full blood count analysis.
Study: NCT00790569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: Given transdermally and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01229904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy with guitar lessons
Description: The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
Study: NCT03185936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy with internal limiting membrane (ILM) peeling
Description: pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
Study: NCT03622710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
Study: NCT03661463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Drug
Study: NCT01912300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental condition: Passvice Video game; Avtive Video game; Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental condition: Passvice Video game; Avtive Video game; Exercise
Study: NCT01855165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice on DDIs
Study: NCT01792401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo